Study (Author, Year)

No. of Patients

% of Patients with Mutations

Schrock et al., 2017 [45]

125

TP53: 74%, KRAS, 34%, MET: 13.6%, EGFR: 8.8%, BRAF: 7.2%, HER2: 1.6%, RET: 0.8%

Li et al., 2017 [46]

7

TP53: 57.1%, MET: 14.1%, APC: 14.1%, HGF: 14.1%, PIK3CA: 14.1%, EGFR: 14.1%, BRAF: 14.1%

Lococo et al., 2016 [7]

49

TP53: 55%, KRAS: 39%, PIK3CA: 12%, STK11: 8%, APC: 6%, PTEN: 6%, BRAF: 2%. EGFR: 2%

Fallet et al., 2015 [47]

81

KRAS: 27.2%, EGFR: 22.2%, TP53: 22.2%, STK11: 7.4%, NOTCH1: 4.9%, NRAS: 4.9%, PI3KCA: 4.9%

Kaira et al., 2015 [48]

17

EGFR: 18%

Cancer Genome Atlas Research Network, 2014 [49]

230

TP53: 46%, KRAS: 33%, STK11: 17%, BRAF: 10%, PIK3CA: 7%, MET: 7%

Chang et al., 2011 [27]

42

TP53: 28.6%, EGFR: 23.8%

Italiano et al., 2009 [50]

22

KRAS: 38%, EGFR: 0%